Many a seasoned and sophisticated biopharma executive have described to me the reality of when an entity does not need to raise capital it should because at some point it will be needed, and by not needing it, the situation may, just may…lend itself to perhaps lowering the cost of capital due in part to [...]

• 454http://clsdf.com/2009/10/allos-get-it-when-you-can/Allos+%7C+Get+it+When+You+Can...2009-10-07+14%3A08%3A00admin

Inviragen (Ft. Collins, CO) a preclinical-stage vaccine company focused on emerging global infectious diseases, closed a $15M Series A financing and in the process merged the assets of Singapore-based SingVax. Participants in the round include Charter Life Sciences, Venture Investors, Bio*One Capital and Phillip Private Equity. This initial round of institutional capital comes on the [...]

• 453http://clsdf.com/2009/10/inviragen-series-a-15m-and-ma/Inviragen+%7C+Series+A+%2415M+and+M%26amp%3BA2009-10-07+13%3A11%3A00admin

GlobeImmune (Louisville, CO) a clinical-stage company focused on developing targeted immunogens for the treatment of cancer and infectious diseases, has had an abstract (“GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves End of Treatment Response at 48 Weeks Versus PEG-IFN/Ribavirin in Naïve Genotype 1 Chronic HCV Patients”) for their investigational hepatitis C virus product candidate accepted for [...]

• 452http://clsdf.com/2009/10/globeimmune-presenting-phase-ii-data-aasld/GlobeImmune+%7C+Presenting+Phase+II+Data+%40+AASLD2009-10-06+14%3A10%3A00admin

Biodesix (Broomfiled, CO) a commercial-stage molecular diagnostics company focused on proteomic-based diagnostics, closed the first tranche of a $10M Series B financing. The company is enabling personalized health care via their mass spectrometry-based molecular profiling proprietary platform technology, ProTS®, to discover and validate diagnostic tests for the improvement of patient outcomes. Biodesix’ first product, VeriStrat®, [...]

• 451http://clsdf.com/2009/10/biodesix-first-tranche-of-10m-series-b/Biodesix+%7C+First+Tranche+of+%2410M+Series+B2009-10-06+13%3A41%3A00admin

In recognition of October as Breast Cancer Awareness Month [C]LSDF is highlighting a few of the early-stage entities who are on the front-line in the battle against breast cancer that have been recently funded and are offering interesting scientific approaches in an effort to yield novel potential treatments, diagnostics and cures. If you are interested [...]

• 450http://clsdf.com/2009/10/october-breast-cancer-awareness-month/October+%7C+Breast+Cancer+Awareness+Month2009-10-04+18%3A10%3A00admin

Part of the [C]LSDF ongoing series Watching the Bio IPO Market. Talecris Biotherapeutics (NASDAQ: TLCR) made a thunderous debut with its Initial Public Offering on the Nasdaq today, offering 50,000,000 shares at $19 and raising $950M in the process. The fun however, did not stop there as the third life science offering of the year [...]

• 449http://clsdf.com/2009/10/talecris-and-then-there-were-three/Talecris+%7C+And+Then+There+Were+Three%212009-10-02+02%3A06%3A00admin

The Rocky Mountain Life Science Investor Conference yielded a sense of sophistication and intensity catalyzed by the aggregation of high-quality presenting companies and top-tier venture and corporate investors. I was hardly surprised that then rumor, hearsay and innuendo combined to yield quite a bit of buzz throughout the oak paneled hallways of the Ritz Carlton [...]

• 448http://clsdf.com/2009/10/tape-delay-from-the-rmlsic-that%e2%80%99s-a-wrap/Tape-Delay+from+the+RMLSIC+%7C+That%E2%80%99s+a+Wrap%212009-10-01+13%3A55%3A00admin